While Dynavax Technologies beat the sales estimates for Q4, the significant year-over-year decrease in sales might raise concerns among investors about the company's growth trajectory. The positive beat against estimates could provide some short-term positive sentiment, but the large decrease in sales compared to the previous year could temper optimism, leading to a neutral short-term impact on the stock price.